Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.2215/CJN.01541005. Epub 2006 Mar 29.
Affiliations
- PMID: 17699248
- DOI: 10.2215/CJN.01541005
Randomized Controlled Trial
Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial
Harmeet Singh et al. Clin J Am Soc Nephrol. 2006 May.
Abstract
Although iron therapy is essential to optimize use of erythropoiesis-stimulating agents (ESA), randomized, controlled trials have heretofore been unavailable to evaluate reliably the efficacy of intravenous iron as an adjuvant to ESA treatment in peritoneal dialysis (PD) patients. In a multicenter trial, patients who had anemia, PD-dependent chronic kidney disease, stable ESA therapy, and a broad range of iron status (ferritin < or = 500 ng/ml, transferrin saturation < or = 25%) were randomly assigned to receive either 1 g of iron sucrose intravenously in three divided doses (300 mg over 1.5 h on days 1 and 15, 400 mg over 2.5 h on day 29) or no supplemental iron. No serious adverse drug events occurred after intravenous iron administration. The primary end point, peak hemoglobin increase, was higher (1.3 +/- 1.1 versus 0.7 +/- 1.1, mean +/- SD; P = 0.0028), and anemia intervention (transfusion, increase in ESA dose, or intravenous iron therapy not called for in protocol) occurred later (P = 0.0137) and less often in intravenous iron-treated patients compared with untreated control subjects (one of 66 [1.3%] versus five of 30 [16.7%]). Among patients who did not require intervention, iron-treated patients showed a calculated net ESA dose decrease compared with untreated control subjects. Baseline iron status did not predict responsiveness to intravenous iron therapy. Intravenous iron sucrose is an effective adjunct to ESA therapy in anemic patients with PD-dependent chronic kidney disease and is administered safely as 300 mg over 1.5 h or 400 mg over 2.5 h. Evidence of iron deficiency at baseline is not required to demonstrate intravenous iron efficacy.
Comment in
- Intravenous iron therapy in peritoneal dialysis patients: short-term efficacy and long-term issues.
Zager RA. Zager RA. Clin J Am Soc Nephrol. 2006 May;1(3):353-5. doi: 10.2215/CJN.00740306. Epub 2006 Apr 5. Clin J Am Soc Nephrol. 2006. PMID: 17699230 Review. No abstract available.
Similar articles
- Comparison of the safety and efficacy of 3 iron sucrose iron maintenance regimens in children, adolescents, and young adults with CKD: a randomized controlled trial.
Goldstein SL, Morris D, Warady BA. Goldstein SL, et al. Am J Kidney Dis. 2013 Apr;61(4):588-97. doi: 10.1053/j.ajkd.2012.10.019. Epub 2012 Dec 12. Am J Kidney Dis. 2013. PMID: 23245582 Clinical Trial. - 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T. Tsubakihara Y, et al. Ther Apher Dial. 2010 Jun;14(3):240-75. doi: 10.1111/j.1744-9987.2010.00836.x. Ther Apher Dial. 2010. PMID: 20609178 - Use of intravenous iron supplementation in chronic kidney disease: an update.
Macdougall IC, Geisser P. Macdougall IC, et al. Iran J Kidney Dis. 2013 Jan;7(1):9-22. Iran J Kidney Dis. 2013. PMID: 23314137 Review. - Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
Kalantar-Zadeh K, Streja E, Miller JE, Nissenson AR. Kalantar-Zadeh K, et al. Adv Chronic Kidney Dis. 2009 Mar;16(2):143-51. doi: 10.1053/j.ackd.2008.12.008. Adv Chronic Kidney Dis. 2009. PMID: 19233073 Review.
Cited by
- Glycosylation and Characterization of Human Transferrin in an End-Stage Kidney Disease.
Miljuš G, Penezić A, Pažitná L, Gligorijević N, Baralić M, Vilotić A, Šunderić M, Robajac D, Dobrijević Z, Katrlík J, Nedić O. Miljuš G, et al. Int J Mol Sci. 2024 Apr 24;25(9):4625. doi: 10.3390/ijms25094625. Int J Mol Sci. 2024. PMID: 38731843 Free PMC article. - Benefits and risks of essential trace elements in chronic kidney disease: a narrative review.
Xie Y, Liu F, Zhang X, Jin Y, Li Q, Shen H, Fu H, Mao J. Xie Y, et al. Ann Transl Med. 2022 Dec;10(24):1400. doi: 10.21037/atm-22-5969. Ann Transl Med. 2022. PMID: 36660676 Free PMC article. Review. - Risk of Infection Associated With Administration of Intravenous Iron: A Systematic Review and Meta-analysis.
Shah AA, Donovan K, Seeley C, Dickson EA, Palmer AJR, Doree C, Brunskill S, Reid J, Acheson AG, Sugavanam A, Litton E, Stanworth SJ. Shah AA, et al. JAMA Netw Open. 2021 Nov 1;4(11):e2133935. doi: 10.1001/jamanetworkopen.2021.33935. JAMA Netw Open. 2021. PMID: 34767026 Free PMC article. - Treatment of Iron Deficiency Anemia in CKD and End-Stage Kidney Disease.
Gutiérrez OM. Gutiérrez OM. Kidney Int Rep. 2021 Jun 5;6(9):2261-2269. doi: 10.1016/j.ekir.2021.05.020. eCollection 2021 Sep. Kidney Int Rep. 2021. PMID: 34514189 Free PMC article. Review. - Anemia Management in Peritoneal Dialysis: Perspectives From the Asia Pacific Region.
Li PKT, Choy ASM, Bavanandan S, Chen W, Foo M, Kanjanabuch T, Kim YL, Nakayama M, Yu X. Li PKT, et al. Kidney Med. 2021 Apr 20;3(3):405-411. doi: 10.1016/j.xkme.2021.01.011. eCollection 2021 May-Jun. Kidney Med. 2021. PMID: 34136787 Free PMC article. Review.